Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.53 |
| ▸ | CKS1B | P61024 | 1/20 | 0.53 |
| ▸ | SKP1 | P63208 | 1/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | SUV39H2 | Q9H5I1 | 6/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389069 | 1.00 | SYK (0.53) | SYKCKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL390147 | 1.00 | SYK (0.53) | SYKCKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL31270899 | 0.94 | MAP4K4 (0.60) | SYKCKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL3025692 | 0.93 | CKS1B (0.60) | SYKCKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL31370459 | 0.91 | PDE10A (0.50) | SYKCKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL596151 | 0.88 | MAP4K4 (0.58) | SYKCKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL529863 | 0.88 | MAP4K4 (0.58) | SYKCKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL594137 | 0.88 | MAP4K4 (0.58) | SYKCKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL1350284 | 0.87 | JAK3 (0.56) | SYKCKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL22826263 | 0.87 | SYK (0.53) | SYKCKS1BSKP1SKP2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101764-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| EP-2029610-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146759-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | SYK 2493/4885CKS1B 3179/4885SKP1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.